Related Experiment Video
Updated: Sep 26, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Combination chemotherapy in the treatment of inoperable non-small cell lung cancer
R M Rutherford1, T Azher, J J Gilmartin
1Department of Respiratory Medicine, Merlin Park Hospital, Galway, Ireland.
Background:
Chemotherapy is an established intervention in inoperable non-small cell lung cancer (NSCLC), yet few Irish patients receive this treatment.
Aim:
To determine survival, toxicity and radiological response following chemotherapy for NSCLC at our institution.
Methods:
Retrospective audit of all patients receiving chemotherapy for histologically proven, inoperable NSCLC from January 1997 to December 2000.
Results:
There were 80 treatment episodes in 77 patients, mean age 62 years. Forty-eight (60%) patients had locally advanced and 32 (40%) metastatic disease. Mitomycin, Ifosfamide, Carboplatin (MIC) and Paclitaxel/Carboplatin (PC) were the most commonly administered regimens. Median survival for locally advanced and metastatic disease was 13.9 months and 7.1 months respectively. Severe neutropenia and thrombocytopenia were each witnessed after less than 9% of cycles. Eleven (16.7%) patients had radiological response including 4 (6.1%) complete responses.
Conclusion:
Survival for inoperable NSCLC treated with chemotherapy was encouraging and achieved at low toxicity.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy